[ipopba/Adobe Stock]
The 2024 JPMorgan Healthcare Conference showcased the resilience and innovation driving the biotech sector, even as the sector has recently grappled with financial headwinds such as declining IPOs, layoffs, and tightening cash reserves. Companies are tightening operations while still pushing forward in developing novel technologies like machine learning for drug discovery, cell and gene therapies, synthetic biology, and unlocking large-scale genomic edits. The CDMO market is also showing signs of renewed growth in early 2024, with opportunities in areas such as advanced therapeutics, oncology, and injectables. Biotech resilience emerging as a theme, but ‘flawless execution’ a need“JPM underscored the resilience of biotechs amid economic challenges, emphasizing strategic priorities like bringing assets into the clinic and an unwavering commitment to timelines,” said M…